Ascend Wellness Holdings (AAWH) Income from Continuing Operations (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Income from Continuing Operations came in at 29493000.0 in Q1 2026, down 53.15% year-on-year from 62947599.91 in Q1 2025, and up 39.44% quarter-over-quarter from 48703000.0 in Q4 2025.
Ascend Wellness Holdings (AAWH) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 29493000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 53.15% year-over-year to 29493000.0 in Q1 2026; TTM through Mar 2026 was 128428000.0, a 49.18% decrease from a year earlier, with the FY2025 full-year figure at 118193000.0, down 39.06% from the prior year.
- Income from Continuing Operations rose to 29493000.0 in Q1 2026 per AAWH's latest filing, from 48703000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 841000.0 in Q2 2023 and bottomed at 48703000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 19343000.0 (2023), against an average of 21281941.18.
- Across the five-year window, Income from Continuing Operations jumped 103.97% in 2023 and plunged 2690.25% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 15050000.0 in 2022, then slipped by 28.52% to 19343000.0 in 2023, then advanced by 13.19% to 16791000.0 in 2024, then plunged by 190.05% to 48703000.0 in 2025, then jumped by 39.44% to 29493000.0 in 2026.
- Per Business Quant, the three latest AAWH Income from Continuing Operations figures stand at 29493000.0 (Q1 2026), 48703000.0 (Q4 2025), and 25825000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn | -29.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.49 Mn |
| Dec 31, 2025 | -48.70 Mn |
| Sep 30, 2025 | -25.83 Mn |
| Jun 30, 2025 | -24.41 Mn |
| Mar 31, 2025 | -19.26 Mn |
| Dec 31, 2024 | -16.79 Mn |
| Sep 30, 2024 | -28.26 Mn |
| Jun 30, 2024 | -21.78 Mn |
| Mar 31, 2024 | -18.16 Mn |
| Dec 31, 2023 | -19.34 Mn |
| Sep 30, 2023 | -11.24 Mn |
| Jun 30, 2023 | 841,000.00 |
| Mar 31, 2023 | -18.47 Mn |
| Dec 31, 2022 | -15.05 Mn |
| Sep 30, 2022 | -16.86 Mn |
| Jun 30, 2022 | -21.17 Mn |
| Mar 31, 2022 | -27.82 Mn |
| Dec 31, 2021 | -16.51 Mn |
| Sep 30, 2021 | -13.03 Mn |
| Jun 30, 2021 | -44.90 Mn |